Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 4, 2025

Primary Completion Date

August 15, 2029

Study Completion Date

August 15, 2029

Conditions

Progressive Multiple Sclerosis

Interventions

BIOLOGICAL

Obecabtagene autoleucel (obe-cel)

Obecabtagene autoleucel (obe-cel) given as a single infusion.

Trial Locations (1)

RECRUITING

University College London Hospital (UCLH), London

All Listed Sponsors

lead

Autolus Limited

INDUSTRY

NCT07139743 - Obe-cel in Refractory Progressive Forms of Multiple Sclerosis | Biotech Hunter | Biotech Hunter